Search

Your search keyword '"MESH: Proguanil"' showing total 4 results
Start Over Descriptor "MESH: Proguanil"
4 results on '"MESH: Proguanil"'

1. Parallel evolution of adaptive mutations in Plasmodium falciparum mitochondrial DNA during atovaquone-proguanil treatment

Author

Lise Musset, Jérôme Clain, Jacques Le Bras, EA 209 - Transports membranaires et chimiorésistances (LABORATOIRE DE PARASITOLOGIE-MYCOLOGIE), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Université Paris Descartes - Paris 5 (UPD5), Institut Pasteur de la Guyane, Réseau International des Instituts Pasteur (RIIP), Centre National de Référence du Paludisme, Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) - Université Paris Descartes - Paris 5 (UPD5), Assistance publique - Hôpitaux de Paris (AP-HP) - AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Descartes - Paris 5 (UPD5), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-AP-HP - Hôpital Bichat - Claude Bernard [Paris], and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)

Subjects
MESH : Molecular Sequence Data, MESH : Cytochromes b, DNA Mutational Analysis, Drug Resistance, MESH: Base Sequence, MESH: Parasitic Sensitivity Tests, MESH : Malaria, Falciparum, Parasitic Sensitivity Tests, MESH : Biological Evolution, MESH : DNA, Mitochondrial, MESH : Proguanil, Genotype, MESH : Plasmodium falciparum, MESH : Parasitic Sensitivity Tests, MESH: Animals, Malaria, Falciparum, MESH: DNA Mutational Analysis, MESH: Plasmodium falciparum, Genetics, 0303 health sciences, biology, Cytochrome b, MESH: Malaria, Falciparum, Cytochromes b, MESH: Proguanil, MESH: Cytochromes b, Biological Evolution, 3. Good health, Proguanil, MESH: Drug Resistance, MESH : Atovaquone, MESH : Mutation, [SDV.MP.PAR] Life Sciences [q-bio]/Microbiology and Parasitology/Parasitology, medicine.drug, Mitochondrial DNA, MESH: Mutation, Molecular Sequence Data, Plasmodium falciparum, MESH: Atovaquone, MESH: Biological Evolution, MESH : DNA Mutational Analysis, DNA, Mitochondrial, MESH: Sequence Homology, Nucleic Acid, Antimalarials, 03 medical and health sciences, Sequence Homology, Nucleic Acid, medicine, Animals, Humans, [SDV.MP.PAR]Life Sciences [q-bio]/Microbiology and Parasitology/Parasitology, MESH : Sequence Homology, Nucleic Acid, Allele, Molecular Biology, Gene, Atovaquone, Ecology, Evolution, Behavior and Systematics, 030304 developmental biology, MESH : Drug Resistance, MESH: Molecular Sequence Data, MESH: Humans, Base Sequence, 030306 microbiology, MESH : Humans, Haplotype, MESH: DNA, Mitochondrial, biology.organism_classification, Atovaquone/proguanil, MESH: Antimalarials, Mutation, MESH : Antimalarials, MESH : Base Sequence, MESH : Animals
Abstract

International audience; Here we provide direct evidence that two adaptive nucleotide changes in the same codon (268) of the cytochrome b gene (pfcytb) each occurred repeatedly in independent Plasmodium falciparum lineages exposed to the antimalarial drug atovaquone-proguanil (AP). We analyzed the history of 7 AP resistance alleles from clinical isolates by sequencing the mitochondrial (mt) genome that encodes the pfcytb gene and found that a distinct mt haplotype was associated with each AP resistance allele. By comparing mt sequences and microsatellite genotypes of the isolates both before treatment initiation and at the day of failure for each uncured patient, we observed that the AP resistance alleles occurred and spread within the patients. These data demonstrate that identical AP resistance alleles have multiple independent origins and provide an example of parallel evolution driven by drug treatment selection in P. falciparum.

Published
2007
Full Text
View/download PDF

2. First case of emergence of atovaquone resistance in Plasmodium falciparum during second-line atovaquone-proguanil treatment in South America

Author

Béatrice Volney, Eric Legrand, Philippe Esterre, Marc Quinternet, Christophe Rogier, Bernard Carme, Odile Puijalon, Magalie Demar, Marie-Thérèse Ekala, Christiane Bouchier, Thierry Fandeur, Institut Pasteur de la Guyane, Réseau International des Instituts Pasteur (RIIP), Unité de Maladies infectieuses et tropicales-Hygiène hospitalière (EA 3593), Centre Hospitalier Andrée Rosemon [Cayenne, Guyane Française], Immunologie moléculaire des parasites, Institut Pasteur [Paris]-Centre National de la Recherche Scientifique (CNRS), Génomique (Plate-Forme) - Genomics Platform, Institut Pasteur [Paris], Immunologie parasitaire (TOURS UMR IMMUNOLOGIE PARASIT), Institut National de la Recherche Agronomique (INRA)-Faculte des Sciences Pharmaceutiques, Unité de Recherche en Biologie et Epidémiologie Parasitaires, Institut de Médecine Tropicale du Service de Santé des Armées-Centre National de la Recherche Scientifique (CNRS), Epidémiologie des parasitoses et mycoses tropicales, Institut National de la Santé et de la Recherche Médicale (INSERM)-Université des Antilles et de la Guyane (UAG), Centre Hospitalier Andrée Rosemon, Génomique (Plate-Forme), Université des Antilles et de la Guyane (UAG)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Pasteur [Paris] (IP)-Centre National de la Recherche Scientifique (CNRS), and Institut Pasteur [Paris] (IP)

Subjects
Drug Resistance, Drug resistance, Pharmacology, MESH: Parasitic Sensitivity Tests, Treatment failure, 0302 clinical medicine, Second line, Parasitic Sensitivity Tests, Pharmacology (medical), MESH: Animals, Malaria, Falciparum, Letter to the Editor, ComputingMilieux_MISCELLANEOUS, MESH: Plasmodium falciparum, 0303 health sciences, biology, MESH: Malaria, Falciparum, MESH: Proguanil, 3. Good health, Infectious Diseases, Proguanil, Combination, MESH: Drug Resistance, Drug Therapy, Combination, Atovaquone, medicine.drug, Falciparum, 030231 tropical medicine, Plasmodium falciparum, MESH: Atovaquone, 03 medical and health sciences, Antimalarials, Drug Therapy, parasitic diseases, medicine, Animals, Humans, [SDV.MP.PAR]Life Sciences [q-bio]/Microbiology and Parasitology/Parasitology, MESH: Humans, 030306 microbiology, MESH: South America, South America, medicine.disease, biology.organism_classification, Atovaquone/proguanil, Virology, MESH: Antimalarials, Malaria, MESH: Drug Therapy, Combination, human activities
Abstract

The atovaquone-proguanil combination (Malarone) has been introduced in French Guiana for prophylaxis and second-line treatment for Plasmodium falciparum malaria in 2002. We report here a treatment failure in a patient who was given a second-line atovaquone-proguanil treatment. A nonimmune P.

Published
2007
Full Text
View/download PDF

3. Clinical atovaquone-proguanil resistance of Plasmodium falciparum associated with cytochrome b codon 268 mutations

Author

Jacques Le Bras, Sophie Matheron, Lise Musset, Olivier Bouchaud, Laurent Massias, Laboratoire de Biologie animale et parasitaire, Université Paris Descartes - Paris 5 (UPD5), Centre National de Référence Paludisme, Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-AP-HP - Hôpital Bichat - Claude Bernard [Paris], Service des maladies infectieuses et tropicales, Hôpital Avicenne-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Université Paris 13 (UP13), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-AP-HP - Hôpital Bichat - Claude Bernard [Paris]-Université Paris Diderot - Paris 7 (UPD7), Laboratoire de Toxicologie, Centre National de Référence du Paludisme, Assistance publique - Hôpitaux de Paris (AP-HP) - AP-HP - Hôpital Bichat - Claude Bernard [Paris], Université Paris 13 (UP13) - Assistance publique - Hôpitaux de Paris (AP-HP) - Hôpital Avicenne, Assistance publique - Hôpitaux de Paris (AP-HP) - AP-HP - Hôpital Bichat - Claude Bernard [Paris] - Université Paris Diderot - Paris 7 (UPD7), Centre National de Référence Paludisme [AP-HP Hôpital Claude Bernard] (CNR), AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Hôpital Avicenne [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris 13 (UP13), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7), and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)

Subjects
Male, MESH : Cytochromes b, Drug Resistance, MESH : Genotype, medicine.disease_cause, MESH: Parasitic Sensitivity Tests, MESH : Malaria, Falciparum, MESH: Genotype, Parasitic Sensitivity Tests, Genotype, MESH : Proguanil, MESH : Plasmodium falciparum, MESH : Parasitic Sensitivity Tests, MESH : Female, MESH: Animals, Malaria, Falciparum, MESH: Plasmodium falciparum, Genetics, 0303 health sciences, Mutation, MESH: Middle Aged, MESH: Codon, Cytochrome b, MESH: Malaria, Falciparum, MESH : Adult, MESH: Proguanil, MESH: Cytochromes b, Cytochromes b, Middle Aged, MESH: Amino Acid Substitution, 3. Good health, Infectious Diseases, Proguanil, MESH: Drug Resistance, Female, MESH : Atovaquone, MESH : Mutation, Atovaquone, medicine.drug, Adult, MESH: Mutation, Adolescent, MESH : Male, Immunology, Plasmodium falciparum, MESH: Atovaquone, Biology, Microbiology, Apicomplexa, 03 medical and health sciences, Antimalarials, MESH : Amino Acid Substitution, MESH : Adolescent, parasitic diseases, medicine, Animals, Humans, MESH : Middle Aged, Codon, 030304 developmental biology, MESH: Adolescent, MESH : Drug Resistance, MESH: Humans, 030306 microbiology, MESH : Codon, MESH : Humans, MESH: Adult, biology.organism_classification, Virology, Atovaquone/proguanil, MESH: Antimalarials, MESH: Male, Amino Acid Substitution, MESH : Antimalarials, MESH : Animals, MESH: Female
Abstract

International audience; Plasmodium falciparum resistance to atovaquone-proguanil has so far been associated with Y268S or Y268N mutations in cytochrome b, although these changes were identified in only seven of the 11 treatment failures. Here, we describe 10 new cases of atovaquone-proguanil treatment failures among which the parasite resistance was confirmed in six cases, either by identifying correct plasma drug concentrations or by observing in vitro atovaquone resistance. Resistance was consistently associated with codon 268 mutations (Y268S or a previously unidentified mutation, Y268C). Notably, mutations were not detected before the treatment but only after the drug exposure.

Published
2006
Full Text
View/download PDF

4. Apparent absence of atovaquone/proguanil resistance in 477 Plasmodium falciparum isolates from untreated French travellers

Author

Lise Musset, Jacques Le Bras, Rémy Durand, Patricia Bigot, Bruno Pradines, Daniel Parzy, Centre National de Référence pour la Chimiosensibilité du Paludisme, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Laboratoire de Biologie Animale et Parasitaire, Université Paris Descartes - Paris 5 (UPD5), Unité de Recherche en Biologie et Epidémiologie Parasitaires, Institut de Médecine Tropicale du Service de Santé des Armées-Centre National de la Recherche Scientifique (CNRS), Unité de Recherche en Pharmacogénétique Parasitaire, Service de Santé des Armées-IFR48, INSB-INSB, Assistance publique - Hôpitaux de Paris (AP-HP)-AP-HP - Hôpital Bichat - Claude Bernard [Paris], Université Paris Descartes - Paris 5 ( UPD5 ), Institut de Médecine Tropicale du Service de Santé des Armées-Centre National de la Recherche Scientifique ( CNRS ), and Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-AP-HP - Hôpital Bichat - Claude Bernard [Paris]

Subjects
Male, MESH : Aged, Drug Resistance, MESH: Parasitic Sensitivity Tests, MESH: Drug Synergism, 0302 clinical medicine, MESH : Child, Parasitic Sensitivity Tests, MESH: Child, MESH : Plasmodium falciparum, Pharmacology (medical), MESH : Parasitic Sensitivity Tests, MESH: Animals, Child, MESH: Naphthoquinones, Aged, 80 and over, 0303 health sciences, MESH: Middle Aged, Cytochrome b, MESH : Infant, Drug Synergism, MESH: Infant, 3. Good health, Child, Preschool, MESH: Drug Resistance, MESH : Atovaquone, Atovaquone, Polymorphism, Restriction Fragment Length, Microbiology (medical), MESH : Drug Synergism, Proguanil, Plasmodium falciparum, 03 medical and health sciences, Antimalarials, MESH : Adolescent, Humans, MESH : Middle Aged, MESH : Aged, 80 and over, Genotyping, Aged, Pharmacology, MESH: Adolescent, MESH : Drug Resistance, MESH: Humans, 030306 microbiology, MESH: Polymorphism, Restriction Fragment Length, MESH : Naphthoquinones, MESH : Humans, MESH: Child, Preschool, Infant, MESH: Adult, Virology, Atovaquone/proguanil, MESH : Antimalarials, MESH: Female, Naphthoquinones, MESH : Cytochromes b, Drug resistance, MESH : Child, Preschool, MESH : Malaria, Falciparum, MESH: Aged, 80 and over, MESH : Proguanil, MESH : Female, Malaria, Falciparum, MESH: Travel, MESH: Plasmodium falciparum, MESH: Aged, Travel, biology, MESH: Malaria, Falciparum, MESH : Adult, Cytochromes b, Middle Aged, MESH: Proguanil, MESH: Cytochromes b, Infectious Diseases, Female, France, Restriction fragment length polymorphism, medicine.drug, Adult, Adolescent, MESH : Male, 030231 tropical medicine, MESH: Atovaquone, parasitic diseases, medicine, Animals, MESH : France, MESH : Polymorphism, Restriction Fragment Length, biology.organism_classification, MESH: Antimalarials, MESH: Male, MESH: France, MESH : Travel, MESH : Animals, human activities
Abstract

Objectives: We examined the atovaquone in vitro susceptibility and the cytochrome b (cytb) gene polymorphism of African Plasmodium falciparum isolates during the first years of atovaquone/proguanil use. Patients and methods: Between 1999 and 2004, we collected blood samples from French P. falciparum-infected patients returning from African countries. Atovaquone susceptibility was determined using an in vitro isotopic test and cytb genotyping was performed by restriction fragment length polymorphism analysis and sequencing. These results were analysed according to the clinical response to atovaquone/ proguanil treatment. Results: No in vitro atovaquone resistance (IC 50 > 1900 nM) and no cytb mutation leading to the Y268S substitution were detected among 477 unexposed African P. falciparumisolates. Eight cytb polymorphisms were found outside the ubiquinone reduction site by sequencing the entire gene of 270 isolates. One atovaquone/proguanil treatment failure was documented; the post-treatment isolate had an atovaquone susceptibility of 8230 nM and the Ser 268 Cytb change; the pre-treatment isolate, obtained 4 weeks previously, was Cytb Tyr 268 (wild-type). Conclusions: No atovaquone/proguanil resistance was detected by phenotyping or genotyping among 477 unexposed African P. falciparum isolates. Atovaquone/proguanil-resistant parasite was detectable only in the post-treatment isolate from a treatment failure.

Published
2006
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results